Skip to main content
. Author manuscript; available in PMC: 2013 Dec 4.
Published in final edited form as: Invest New Drugs. 2009 Jul 2;28(5):10.1007/s10637-009-9279-8. doi: 10.1007/s10637-009-9279-8

Fig. 3.

Fig. 3

Results of mutational analysis of tumors for ras codon 12 and 13 and braf. DNA was extracted from formalin fixed paraffin embedded tissue, PCR amplified, and analyzed by pyrosequencing. Panel a: Sample from patient in first dose cohort, showing the wild type ras sequence, GGT. Panel b: Sample from the patient with breast cancer who experienced a partial response (# 501-Table 4), showing the mutated ras sequence, GCT. Panel c: Sample from patient in first dose cohort, showing the wild type braf sequence, GTG. Panel D: Sample from the patient with breast cancer (# 502-Table 4), showing the mutated braf sequence GAG